

LIFE-CHANGING TECHNOLOGY
RISES TO THE TEST

SALES WORLDWIDE

\$7.3B

SALES PERFORMANCE
ACROSS ABBOTT

 \$2B
DIAGNOSTICS

 \$1.9B
NUTRITION

 \$2.4B
MEDICAL DEVICES

 \$1B
ESTABLISHED
PHARMACEUTICALS

FULL-YEAR 2020 EPS GUIDANCE¹

at least \$3.25

ADJUSTED DILUTED EARNINGS PER SHARE

LEADER IN
GLOBAL COVID-19 TESTING

Launched
5 COVID-19
TESTS

• 2 lab-based molecular tests to detect the virus



• 1 rapid molecular test to detect the virus



• 2 lab-based antibody tests that can indicate previous infection



~40M

COVID-19
TESTS SOLD
WORLDWIDE

MORE TESTS IN THE PIPELINE
**TO HELP TEST AS MANY
PEOPLE AS POSSIBLE**

STRENGTH IN OUR DIVERSIFIED BUSINESS



FreeStyle Libre
SALES UP **40%**²

ON ORGANIC BASIS*

- ▶ Announced U.S. FDA clearance of FreeStyle Libre 2^{®†}, an integrated continuous glucose monitoring (iCGM) system for adults and children (ages 4 years and older) with diabetes, achieving the highest levels of accuracy and performance standards with optional real-time alarms
- ▶ Announced collaboration with Tandem Diabetes Care for integrated solutions that combine FreeStyle Libre technology with Tandem insulin delivery products

Diagnostics
SALES UP **7%**³

ON ORGANIC BASIS*

- ▶ Molecular Diagnostics sales up 241%³ and Rapid Diagnostics sales up 11%³, both on an organic basis* and due to incredibly high demand for our COVID-19 tests
- ▶ Announced two new COVID-19 tests, bringing our molecular and antibody tests to our high-throughput Alinity diagnostic instruments



- ▶ Announced CE Mark for TriClip™ Transcatheter Tricuspid Valve Repair System, world's first minimally invasive clip-based tricuspid heart valve repair device
- ▶ Announced U.S. FDA approval of Gallant™ implantable cardioverter defibrillator devices of devices to help manage heart rhythm disorders



Secured Approvals
FOR IMPORTANT
HEART DEVICES

*Organic sales growth excludes impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated July 16, 2020, available at www.abbottinvestor.com.

1. Adjusted diluted EPS excludes specified items. Abbott forecasts specified items for the full-year 2020 of \$1.25 primarily related to intangible amortization, acquisition-related expenses, restructuring and cost reduction initiatives and other expenses. On a GAAP basis, full-year diluted EPS guidance is at least \$2.00. 2. On a GAAP basis, FreeStyle Libre sales increased 37%. 3. On a GAAP basis, Diagnostics sales increased 5%; Molecular Diagnostics sales increased 234%; and Rapid Diagnostics sales increased 10%.

† Find important safety information about the FreeStyle Libre portfolio: www.freestylelibre.us/safety-information.

FORWARD-LOOKING STATEMENTS

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties, including the impact of the COVID-19 pandemic on Abbott's operations and financial results, that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" to our Annual Report on Form 10-K for the year ended Dec. 31, 2019 and in Item 1A, "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.